Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00191750 · ClinicalTrials.gov registry record · Phase 2
A Study of Pemetrexed in Small Cell Lung Cancer, Which Has Returned
A Phase 2 study of Carcinoma, Small Cell, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 3
- Study locations
NCT00191750: Completed Phase 2 study of Carcinoma, Small Cell, sponsored by Eli Lilly and Company.
NCT00191750 is a Phase 2 study of Carcinoma, Small Cell that has completed, run by Eli Lilly and Company. The registered enrollment target is 80 participants, below the 100-participant average among 3 other Carcinoma, Small Cell trials with a reported enrollment target (20% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00191750, a Phase 2 study of Carcinoma, Small Cell, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purposes of this study are to determine 1) the safety of pemetrexed and any side effects that might be associated with it 2) whether pemetrexed can help patients with small cell lung cancer live longer 3) whether pemetrexed can make tumors smaller or disappear and for how long and 4) to see if patients feel better while taking pemetrexed
Conditions Studied
Interventions
- DRUG Pemetrexed
Study Locations (3)
Colorado
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician - Aurora
North Carolina
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician - Chapel Hill
Texas
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2004-07 |
| Est. Completion | 2006-09 |
| Phase | Phase 2 |
What the finished NCT00191750 record still lists
NCT00191750 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 100-participant average among 3 other Carcinoma, Small Cell trials with a reported enrollment target (20% lower).
The record links to 1 condition, with Carcinoma, Small Cell appearing as the primary indexed condition, and to 1 intervention - of which Pemetrexed is the first listed.
NCT00191750 reports a single indexed study location in Colorado, North Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT00191750 about?
NCT00191750 is a clinical study titled "A Study of Pemetrexed in Small Cell Lung Cancer, Which Has Returned". The purposes of this study are to determine 1) the safety of pemetrexed and any side effects that might be associated with it 2) whether pemetrexed can help patients with small cell lung cancer live longer 3) whether pemetrexed can make tumors smaller or disappear and for how long and 4) to see if p...
What is the current status of trial NCT00191750?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2004-07. Estimated completion is 2006-09.
What conditions does trial NCT00191750 study?
This clinical trial studies the following conditions: Carcinoma, Small Cell.
What interventions are being tested in trial NCT00191750?
The interventions under investigation include: Pemetrexed (DRUG).
Who is sponsoring clinical trial NCT00191750?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00191750 being conducted?
This trial has 3 study locations across Colorado, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Small Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer
COMPLETED · Phase 2
-
Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer
COMPLETED · Phase 2
-
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia